PPARG and type 2 diabetes mellitus: Selective activators of PPARγ, such as glitazones, havebeen successfully used to treat T2DM for nearly a decade.Treatment with rosiglitazone and pioglitazone induce body weightgain in mice [45, 46, 49], rats [44, 47–50],nonhuman primates [51, 52], and humans [53–55].Weight gain is manifested as increased adiposity, total body waterand plasma volume.